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http://www.retrovirology.com/content/10/1/136RESEARCH Open AccessDual-acting stapled peptides target both HIV-1
entry and assembly
Hongtao Zhang1†, Francesca Curreli1†, Abdul A Waheed2†, Peter Y Mercredi3, Mansi Mehta3, Pallavi Bhargava3,
Daniel Scacalossi1, Xiaohe Tong4, Shawn Lee4, Alan Cooper5, Michael F Summers3, Eric O Freed2
and Asim K Debnath1*Abstract
Background: Previously, we reported the conversion of the 12-mer linear and cell-impermeable peptide CAI to a
cell-penetrating peptide NYAD-1 by using an i,i + 4 hydrocarbon stapling technique and confirmed its binding to
the C-terminal domain (CTD) of the HIV-1 capsid (CA) protein with an improved affinity (Kd ~ 1 μM) compared to
CAI (Kd ~ 15 μM). NYAD-1 disrupts the formation of both immature- and mature-like virus particles in in vitro and
cell-based assembly assays. In addition, it displays potent anti-HIV-1 activity in cell culture against a range of
laboratory-adapted and primary HIV-1 isolates.
Results: In this report, we expanded the study to i,i + 7 hydrocarbon-stapled peptides to delineate their mechanism
of action and antiviral activity. We identified three potent inhibitors, NYAD-36, -66 and −67, which showed strong
binding to CA in NMR and isothermal titration calorimetry (ITC) studies and disrupted the formation of mature-like
particles. They showed typical α-helical structures and penetrated cells; however, the cell penetration was not as
efficient as observed with the i,i + 4 peptides. Unlike NYAD-1, the i,i + 7 peptides did not have any effect on virus
release; however, they impaired Gag precursor processing. HIV-1 particles produced in the presence of these peptides
displayed impaired infectivity. Consistent with an effect on virus entry, selection for viral resistance led to the
emergence of two mutations in the gp120 subunit of the viral envelope (Env) glycoprotein, V120Q and A327P,
located in the conserved region 1 (C1) and the base of the V3 loop, respectively.
Conclusion: The i,i + 7 stapled peptides derived from CAI unexpectedly target both CA and the V3 loop of
gp120. This dual-targeted activity is dependent on their ability to penetrate cells as well as their net charge. This
mechanistic revelation will be useful in further modifying these peptides as potent anti-HIV-1 agents.
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Human immunodeficiency virus type 1 (HIV-1) is the
etiological agent of acquired immunodeficiency syndrome
(AIDS). The AIDS epidemic remains a major health crisis
worldwide – According to the 2012 AIDS Epidemic
Update (UNAIDS) approximately 34 million people are
currently living with HIV/AIDS, which is the sixth leading
cause of death worldwide and the third among low-income
groups (WHO fact sheets, June 2011). Approximately 30* Correspondence: adebnath@nybloodcenter.org
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reproduction in any medium, provided the oranti-HIV drugs have been approved by the US FDA, a
majority of which target one of the three key viral enzymes:
reverse transcriptase (RT), protease (PR), and integrase
(IN). The first inhibitor of viral entry, Enfuvirtide, was
approved in 2003 [1,2] and another entry inhibitor tar-
geted to the CCR5 receptor, Maraviroc, was approved
[3]. The introduction of highly active antiretroviral therapy
(HAART) has significantly decreased morbidity and mor-
tality among HIV-1-infected patients with access to these
drugs. However, the development of drug resistance and
issues related to drug tolerability and compliance often
pose a considerable challenge to current therapies [4-8].
These concerns, together with recent reports of failure in
clinical trials of HIV vaccines and several microbicides,Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the development of novel classes of anti-HIV-1 drugs.
The HIV-1 genome is composed of three major genes,
gag, pol and env. The gag gene encodes the Gag protein,
the critical structural protein of HIV-1. The pol gene
encodes the aforementioned viral enzymes, which are
essential for HIV-1 replication. The env gene encodes
the viral envelope (Env) glycoproteins, which play a crit-
ical role in virus entry. Virus assembly is a key step in
the HIV-1 life cycle, which occurs through the controlled
polymerization of the Gag polyprotein [9-11] to form
spherical immature non-infectious virus particles that
bud out from the plasma membrane. During or shortly
after virus release, the particles undergo a process known
as maturation. During this step, the Gag polyprotein
precursor is sequentially cleaved by PR to matrix (MA),
capsid (CA), nucleocapsid (NC), and p6 domains, as well
as two spacer proteins (SP1 and SP2). This process trig-
gers a dramatic change in particle morphology during
which the CA protein, liberated from the Gag precursor,
reassembles into a conical core that surrounds the viral
genome. After the virus enters the cell, the conical core
undergoes controlled disassembly concomitant with the
conversion of the single-stranded viral RNA genome to
double-stranded DNA by RT [12-14]. CA thus plays an
important role in both the early and late stage of HIV
replication, making it an attractive target for novel anti-
HIV drugs [15-22].
In 2005, a 12-mer peptide (CAI), identified by phage-
display, was reported to disrupt both immature- and
mature-like particles in vitro by targeting the C-terminal
domain (CTD) of HIV-1 CA [21]. However, it could not
inhibit HIV-1 in cell culture due to its lack of cell perme-
ability [23]. Subsequently, we converted CAI to a cell-
penetrating peptide (NYAD-1) by using a hydrocarbon
stapling technique and confirmed its binding to the CTD
[24]. NYAD-1, which is an i,i + 4 staple peptide, disrupts
the formation of both immature- and mature-like particles
in cell-free and cell-based assembly systems. In addition,
NYAD-1 displays potent anti-HIV-1 activity in cell culture
against a range of laboratory-adapted and primary HIV-1
isolates (4.2 – 21 μM). It binds to a hydrophobic pocket,
identified previously in x-ray studies of CTD complexed
with CAI [25], with an improved affinity (Kd ~ 1 μM)
compared to CAI (Kd ~ 15 μM) [24].
Here we report the mechanism of action and antiviral
activity of a series of i,i + 7 stapled peptides derived from
CAI. We show that this class of stapled peptides inhibit
both assembly of infectious HIV-1 and its entry; thereby
acting as dual-targeted inhibitors. NMR studies indicate
that these stapled peptides strongly bind to HIV-1 CA,
although not all of them significantly perturb in vitro
CA assembly. In addition, the ability of these peptides to
inhibit virus assembly appears to be dependent on theefficiency of cell penetration. Resistance studies to delin-
eate the target and mechanism of inhibition suggested the
involvement of the gp120 V3 loop, a region of gp120
critical for Env-mediated membrane fusion and viral
infection [26,27]. Biophysical studies using isothermal
titration calorimetry (ITC) confirmed that these peptides
bind strongly to the V3 loop. The critical findings detailed
here illustrate dual inhibition of HIV-1 assembly and viral
entry through specific targeting of HIV-1 CA and gp120,
respectively.
Results
i,i + 7 stapled peptides show antiviral potency in multi-cycle
infection assay
We used a multi-cycle infectivity assay as a first-step screen-
ing tool to measure the anti-HIV-1 activity of 16 i,i + 7 sta-
pled peptides using laboratory-adapted, X4-tropic HIV-1
IIIB in MT-2 cells. We measured the inhibition of p24
production in MT-2 cells treated over a range of con-
centrations of peptides and calculated the concentration
required to inhibit 50% of the production of p24 (IC50).
We also evaluated the cytotoxicity of the stapled peptides
by the XTT method [28]. The cytotoxicity assessment was
performed in parallel with the HIV-1 inhibition assay.
The results (Table 1) indicate that NYAD-36, NYAD-66
and NYAD-67 display the best antiviral activity and in-
hibit infection by HIV-1 IIIB with low-μM potency
(IC50 ~ 1.5-3.9 μM). These peptides also have a good se-
lectivity index (SI = CC50/IC50) ranging from >27-126.
We have selected these three peptides for subsequent
studies for delineating their mechanism of action.
Hydrocarbon stapling enhances α-helicity of the
stapled peptides
Previously we have shown that the α-helical character-
istics of i,i + 4 stapled peptides such as NYAD-1 and
NYAD-201 is essential for these peptides to penetrate
cells in order for them to target HIV-1 CA and inhibit
virus assembly and maturation [19,24]. In this study, we
also used circular dichroism (CD) to characterize the
secondary structure of i,i + 7 stapled peptides and a lin-
ear version of the NYAD-36 in solution, NYAD-41. The
stapled peptides showed typical α-helical spectra with
minima at 222 and 208 nm; whereas the linear peptide,
NYAD-41, did not show these minima, indicative of a
random structure in solution (Figure 1). The data
confirm that i,i + 7 hydrocarbon stapling enhances the
α-helicity of the linear peptide, NYAD-41, as previously
reported [19,24].
i,i + 7 Stapled peptides penetrate cells less efficiently
than i,i + 4 stapled peptides
With the exception of select positively charged peptides,
the electrostatic charge of amino acid side chains and
Table 1 Antiviral activity (IC50) and cytotoxicity (CC50) of i & i + 7 stapled peptides against HIV-1IIIB in MT-2 cells
Peptide Sequence Net charge IC50 (μM± SD) in MT-2 CC50 (μM± SD) in MT-2 SI
CAI ITFEDLLDYYGP-amide (Linear reference) −2 >100 >100 >1.0
NYAD-401 Ac-IRQGPKEPFRDYVDR-amide (Linear control for NMR) 1 >100 >100 >1.0
NYAD-41 Ac-ISFDELLDYYGESGS (linear control based on NYAD-36) −5 >100 >100 >1.0
NYAD-33 Ac-ISF-R8-EWLQYY-S5-R-amide 0 3.37 ± 0.06 9.2 ± 0.26 2.7
NYAD-36 Ac-ISF-R8-ELLDYY-S5-ESGS-amide −4 1.5 ± 0.17 >189.4 >126
NYAD-43 Ac-ISF-R8-ELEDYY-S5-ESGS −5 >53.34 >106.6 >2.0
NYAD-44 Ac-ISF-R8-ELLDYY-S5-ESGSKKK-amide 0 11.7 ± 1 17.2 ± 1.4 1.5
NYAD-46 Ac-ISF-R8-QLLDYY-S5-QSGSK-amide 0 5.5 ± 1 10.6 ± 0.6 1.9
NYAD-55 Ac-ISF-R8-ELLDYY-S5-EKSGSKD-amide −2 >89.7 >89.7 >1.0
NYAD-56 Ac-ISF-R8-ELLRYY-S5-R-amide 1 4.8 ± 0.9 16.4 ± 1.2 3.4
NYAD-57 ISF-R8-ELLNYY-S5-ESGS-amide −1 8.7 ± 0.7 39.6 ± 4.4 4.5
NYAD-58 IRF-R8-QLLNYY-S5-ESGS-amide 1 6.9 ± 0.06 14.9 ± 1 2.1
NYAD-61 Ac-RSF-R8-RLLDYY-S5-ESGS-amide 0 10.2 ± 1.1 31.7 ± 1.4 3.1
NYAD-62 Ac-RRF-R8-ELLDYY-S5-ESGS-amide −1 8 ± 0.3 15.4 ± 0.2 1.9
NYAD-63 Ac-R-R8-FAELLD-S5-YGESGS-amide −2 57.1 ± 3.2 >113 >2.0
NYAD-64 Ac-SK-R8-ELLDYY-S5-ESGS-amide −2 >109 >109 >1.0
NYAD-65 Ac-RSFE-R8-LLDYYG-S5-SGS-amide −1 >116 >116 >1.0
NYAD-66 Ac-ISF-R8-ELLDYY-S5-ED-amide −4 3.94 ± 0.32 >115 (0%)a >29.1
NYAD-67 Ac-ISF-R8-EWLQAY-S5-EDE-amide −4 3.88 ± 0.3 >107.4 (0%)a >27.7
aThe number in parenthesis indicates % toxicity at that dose; S5 [(S)-2-(4′-pentenyl)alanine] and R8 [(R)-2-(7′-octenyl)alanine] indicate stapling sites in the
peptide sequence.
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the transduction of peptides across cellular membranes.
Our previous reports demonstrated that i,i + 4 stapled
peptides efficiently penetrate 293T cells. The net charge
of the i,i + 4 stapled peptide NYAD-1 is 0 while the net
charge of each of the three selected i,i + 7 stapled pep-
tides is −4. To test if the −4 net charges would affect the
translocation of i,i + 7 stapled peptides across the plasmaM
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Figure 1 CD spectra of NYAD-41, NYAD-36, NYAD-66 and NYAD-67 to
25°C in 1x PBS in the presence of 1%–20% (v/v) acetonitrile at a final conce
showed typical wavelength minima at 208 nm and 222 nm, whereas NYADmembrane, we used confocal microscopy (Additional file 1:
Figure S1) and FACS analysis (Figure 2) to study the cell
penetration of these peptides. The mean fluorescence
intensity (MFI) was used to quantify the cellular uptake
of FAM-conjugated peptides. We used NYAD-1 as a con-
trol. The data in Additional file 1: Figure S1 and Figure 2
indicate that NYAD-36, NYAD-66 and NYAD-67 appar-
ently penetrate cells less efficiently than NYAD-1 under240 260
 (nm)
NYAD-41
NYAD-36
NYAD-66
NYAD-67
measure their secondary structures. CD spectra were measured at
ntration of peptide of 100 μM. NYAD-36, NYAD-66 and NYAD-67
-41 showed a minimum at 205 nm.
Figure 2 Cell penetration of staple peptides in 293T cells. FACS analyses of 293T cells incubated with 4 μM FAM-conjugated peptides for 20 h at
37°C. The cells were treated with 0.25% Trypsin-EDTA for 30 min at 37°C and washed twice with 1x PBS before and after Trypsin-EDTA treatment. The
experiment was repeated twice with similar results. The mean fluorescence intensity (MFI) was used to quantify the cellular uptake of FAM-conjugated
peptides. NYAD-1 was used as positive control and a FAM-conjugated linear peptide, NYAD-41, was used as a negative control.
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Figure 3 Overlay of 2D 1H-15N HSQC spectra obtained for the
HIV-1 capsid monomer (P24-W184A/M185A) protein upon titration
with NYAD-36. Ratios are as follows, 0:1 (Black) and 2:1 (Red),
NYAD-36:P24.
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peptides NYAD-66 and NYAD-67 showed a better pene-
tration profile than NYAD-36.
i,i + 7 stapled peptides bind HIV-1 CA
1H-15N heteronuclear single quantum coherence (HSQC)
NMR spectra were obtained for a monomeric CA con-
struct containing mutations designed to inhibit CA-CA
interactions (W184A/M185A mutations) [29-31]. Spectra
were obtained for proteins in the absence and presence
of NYAD-36, -66 and −67 peptides and were analyzed
using previously reported NMR signal assignments [24,29].
Titrations with stapled peptides NYAD-36, and −66
and −67 resulted in significant NMR spectral changes
consistent with tight binding, and all but a few of the
affected signals were associated with residues of the
CA C-terminal domain, as expected [32]. Representa-
tive 1H-15N HSQC spectra obtained upon titration of
NYAD-36 into HIV-1 CA are shown in (Figure 3). The
spectral changes are consistent with those observed
upon titration of NYAD-1 into the isolated CA-CTD
domain [24].
i,i + 7 stapled peptides bind to the CA CTD with an
affinity similar to that of the i,i + 4 peptide, NYAD-1
We used isothermal titration calorimetry (ITC) to estimate
the binding affinity (expressed as the dissociation constant
Kd) of NYAD-36, NYAD-66 and NYAD-67 to the double-
mutant version (W184A/M185A) of the CA CTD. The
double-mutant CTD was used to avoid CA dimer for-
mation observed with the WT CTD. The stoichiometry(n), affinity (Kd), and thermodynamic parameters such
as ΔH and ΔS, were obtained and the data were analysed
using MicroCal Origin 7.0 software. The integrated bind-
ing isotherms (Additional file 1: Figure S2a-c) were fit
to a single-site binding model. The binding affinities
of NYAD-36, NYAD-66 and NYAD-67 were 10.12 ±
1.4 μM, 3.60 ± 0.16 μM and 2.63 ± 0.22 μM, respectively.
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CA was 2.00 ± 0.19 μM (Additional file 1: Figure S2d).
NYAD-36 showed ~ 3-5-fold lower affinity towards the
CA CTD compared to NYAD-1, -66 and −67.
i,i + 7 stapled peptides disrupt CA assembly in vitro
It has been demonstrated previously that under appro-
priate conditions HIV-1 CA will assemble into tubes in
which the CA monomers are arranged in a hexameric
lattice analogous to that found in the mature, conical
core [33-35]. This in vitro assembly reaction is thus
useful for examining the effect of CA-binding inhibitors
on core assembly. We used this approach to evaluate
the effect of NYAD-36, -66 and −67 on CA assembly [19].
Assembly reactions were performed with no peptide
(control) or an increasing dose of 0.25- to 3.0-fold molar
equivalent of NYAD-36. In the presence of peptide, the
CA tubes that formed were either severely damaged or
disintegrated (Figure 4a). A clear dose–response effect
was observed (Figure 4b). NYAD-1 was used as a control.
A similar trend in preventing tube assembly was observed
with NYAD-66 and NYAD-67 (data not shown).
The ability of stapled peptides to disrupt CA-CA inter-
actions was also assessed using a turbidity-based in vitro
CA assembly assay. This assay is based on the observa-
tion that the turbidity of a CA-containing solution in-
creases in proportion to the extent of assembly [18,36].Control
f
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Figure 4 Inhibition of in vitro assembly by NYAD-36. Negatively stained
CA proteins in the presence of (a) no peptide (Control), 0.25-, 0.5-, 1.0-, and 3-
molar equivalent of NYAD-1. (b) Quantification of mature-like particles resultin
(Control), 0.25-, 0.5-, 1.0-, 3.0-fold molar equivalent of NYAD-36.A control peptide comprising the sequence for the cap-
sid major homology region (MHR), NYAD-401, had no
observable effect on CA assembly, as expected. Com-
pounds NYAD-36 and NYAD-66 both reduced the extent
of CA assembly in a dose-dependent manner, exhibiting
maximal effect at a CA:peptide ratio of 1:1 (Figure 5).
Interestingly, although NMR studies clearly show that
NYAD-67 binds tightly to CA, the binding did not influ-
ence the rate or extent of CA assembly in this in vitro
assay (Figure 5).
i + 7 stapled peptides impair Gag processing without
inhibiting virus release
We have shown previously that NYAD-1, an i,i + 4 sta-
pled peptide derived from CAI, inhibited HIV-1 release
in a dose-dependent manner. This inhibition was specific
to HIV-1 as the release of another lentivirus, equine infec-
tious anemia virus (EIAV), was not inhibited [24]. In this
study we investigated whether i,i + 7 stapled CAI-derived
peptides have any effect on virus release. 293T cells were
transfected with the full-length HIV-1 molecular clone
pNL4-3, treated with stapled peptides for 16–20 h, and
metabolically labeled with [35S]Met/Cys. The cell- and
virus-associated proteins were immunoprecipitated with
HIV-Ig. Unlike NYAD-1, these analogs showed little to
no inhibition of HIV-1 release (Figure 6a; Additional file 1:
Figure S3). However, as we had observed previously withAD-1
b
Control 0.25X 0.5X 1 X 3 X
EM images of mature-like particles resulting from in vitro assembly of
fold molar equivalent of NYAD-36. and 0.25-, 0.5-, 1.0-, 3.0- and 5-fold
g from in vitro assembly of CA proteins in the presence of no peptide
Figure 5 Turbidity assay results showing the effects of CA-binding
to staple peptides on in vitro capsid assembly. Compound: CA ratios
and initial rates [millioptical density units (mOD)] per minute, reported
as the mean ± standard deviation from three experiments) are as
follows: red, 2:1 NYAD-401 (does not bind CA) (223 ± 32.5 mOD/min);
black, 1.2uL DMSO control (216 ± 6.23 mOD/min); blue, 2:1 NYAD-67
(205 ± 18.89 mOD/min); green, 2:1 NYAD-66 (166 ± 18.91 mOD/min);
orange, 2:1 NYAD-36 (158 ± 24.71 mOD/min).
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stapled peptides (NYAD-36, -66, and −67) led to a mod-
est accumulation of cell-associated Pr55Gag (Figure 6b;
Additional file 1: Figure S3).
HIV-1 particles produced in the presence of stapled
peptides display impaired infectivity
Proper Gag processing is required for particle maturation
and infectivity [37,38]. Since Pr55Gag processing was
reduced in the presence of i,i + 7 stapled peptides, we
investigated whether the infectivity of virions produced in
the presence of these peptides was inhibited. Six hours
posttransfection, 293T cells were treated with the indi-
cated concentrations of the peptides for two days and
virus supernatants were collected and monitored for RT
activity. The indicator cell line TZM-bl was infected with
RT-normalized virus for 2 h. As shown in Figure 7, the
virions produced from cells treated with 50 μM NYAD-67
showed a two-log reduction in infectivity. The infectivity
defect was more moderate (four-fold) at similar concen-
trations of NYAD-36 and −66.
Selection of i + 7 stapled peptide-resistant virus
The data presented above indicate that stapled peptides
disrupt Pr55Gag processing and reduce particle infectivity.
To elucidate the mechanism(s) by which the infectivity
of virions produced in the presence of stapled peptideswas reduced, we selected for viral resistance. We used
NYAD-36, a moderate inhibitor among the three stapled
peptides, for the selection experiments. The Jurkat
T-cell line was transfected with pNL4-3, and virus
replication was monitored by RT activity in the presence
of 25, 37.5, and 50 μM NYAD-36. In the absence of
NYAD-36 and in the presence of 25 μM peptide, virus
replication peaked approximately six days posttransfec-
tion. However, in the presence of 37.5 μM NYAD-36
virus replication was significantly delayed, with peak RT
levels occurring at six weeks posttransfection (Figure 8).
At 50 μM NYAD-36 no replication was detected even
three months posttransfection (Figure 8, data not shown).
To determine whether the delayed HIV-1 replication was
due to emergence of resistance, we repassaged the virus
collected on day 41 in the presence of 37.5 μM NYAD-36
in parallel with virus obtained from untreated cultures.
We observed that the virus obtained from NYAD-36-
treated cells showed comparable replication kinetics in
the absence and presence of 37.5 μM NYAD-36, whereas
the replication of WT virus was delayed under these
conditions (data not shown). This analysis demonstrated
that a resistant virus had emerged in the cultures treated
with 37.5 μM NYAD-36.
Identification and characterization of NYAD-36-resistant
mutants
To identify the change(s) responsible for NYAD-36 re-
sistance, viral genomic DNA was purified from infected
cells at the peak of RT activity. We amplified the gag and
env coding regions by PCR, and sequenced the PCR prod-
ucts. In two independent experiments, two mutations,
V120Q and A327P, were identified in the gp120-coding
portion of the env gene whereas no changes were
observed in the gag gene. V120Q is located in constant
region 1(C1); A327P is at the base of the V3 loop. The
appearance of mutations in env is intriguing as the sta-
pled peptides are designed to bind CA. We next sought
to confirm that the selected mutations confer resistance
to the stapled peptides by constructing pNL4-3 deriva-
tives containing both V120Q and A327P substitutions.
Since the NYAD-36-resistance mutations are located
in env, we carried out single-cycle infectivity assays.
TZM-bl cells were infected with WT and mutant HIV-1 in
the absence of peptides or in the presence of NYAD-36, -66,
or −67, and luciferase activity was measured two days
post-infection. As shown above (Figure 9), the infectivity
of the WT was reduced in a dose-dependent manner by
all three peptides; at a 50 μM concentration virus infect-
ivity was reduced >10-fold and >40-fold in the presence
of NYAD-36 and NYAD-67, respectively, and around
3-fold with NYAD-66 at this concentration (Figure 9).
In contrast, the infectivity of the V120Q/A327P double
mutant was reduced by only ~2.5-fold at 50 μM NYAD-36
Figure 6 i + 7 stapled peptides have no effect on HIV-1 release, but impair Gag processing. (a) 293T cells were transfected with pNL4-3
and 6 h after transfection treated with indicated concentrations of NYAD-36, -66, and −67 for 16–20 h. Cells were metabolically labeled with [35S]
Met/Cys for 2 h. Cells were lysed and virions were collected by ultracentrifugation. Cell and virus lysates were immunoprecipitated with HIV-Ig
and subjected to SDS-PAGE. Protein band intensities were quantified by phosphorimager analysis, and HIV-1 release was calculated as the amount
of virion-associated p24 relative to total (cell- plus virion-associated) Gag. (b) Accumulation of unprocessed Gag in cells was measured by calculating
the ratio of Pr55Gag to p24 in cells. P values were calculated by Student’s t-test, with P < 0.05 considered significant. N = 3, ± SD.
Figure 7 HIV-1 particles produced in the presence of stapled peptides show defects in infectivity. Six hours posttransfection with pNL4-3,
293T cells were treated with indicated concentrations of NYAD-36, -66, and −67 and virions were collected after 2 days. RT-normalized virus stocks
were used to infect TZM-bl cells for 2 h in a total volume of 100 μl (the concentration of peptides from producer cells was diluted ~20-fold). Two
days after infection, cells were washed, lysed and assayed for luciferase activity. N = 8, ± SD.
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Figure 8 Selection for NYAD-36-resistant virus. Jurkat cells were transfected with pNL4-3 and cultured in the presence of 25, 37.5 and 50 μM
NYAD-36. Cells were split every 2 days and HIV-1 replication was monitored by RT activity. The results are representative of at least two
independent experiments.
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NYAD-66 (Figure 9). These data demonstrate that the
V120Q/A327P mutations in gp120 confer a marked de-
gree of resistance to the peptides NYAD-36, -66, and −67
in single-cycle infectivity assays. We also tested the
infectivity of WT and V120Q/A327P mutant virus in
the presence of the previously described [24] peptide
NYAD-1. The infectivity of both WT and the V120Q/
A327P mutant was reduced to a similar extent (~10-fold)
in the presence of NYAD-1 (Additional file 1: Figure S4)Figure 9 Mutations in the HIV-1 Env confer resistance to stapled pep
to TZM-bl cells at indicated concentrations during the 2 h infection for WT
were washed and luciferase activity was measured as in Figure 7. N = 3, ±indicating that the gp120 mutations do not confer re-
sistance to NYAD-1.
We next examined whether the V120Q/A327P Env mu-
tant is resistant to the peptides in spreading virus replica-
tion assays. Jurkat cells were transfected with WT or the
V120Q/A327P Env mutant derivative, and replication was
monitored in the absence or presence of 37.5 μM stapled
peptides. In the absence of peptide, virus replication
kinetics of the V120Q/A327P mutant were comparable
to those of the WT. Replication of the WT was significantlytides in single-cycle infectivity assay. Stapled peptides were added
and Env mutant (V120Q/A327P) viruses. Two days after infection cells
SD.
Figure 10 Env mutant V120Q/A327P replicates in the presence of stapled peptides. Replication of WT and V120Q/A327P Env mutant was carried in
the presence of 37.5 μM stapled peptides as described in the Figure 8 legend. The results are representative of at least two independent experiments.
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(NYAD-67) in the presence of peptide; in contrast, none
of the three peptides had a significant effect on the repli-
cation of the V120Q/A327P mutant (Figure 10). These re-
sults demonstrate that the V120Q/A327P mutant is
resistant to these stapled peptides in spreading infections
in the Jurkat T-cell line.
To evaluate the effects of the peptides on replication
of WT and the V120Q/A327P mutant in primary human
cells, we used these viruses to infect peripheral blood
mononuclear cells (PBMC) from three different donors
and propagated the infected cultures in the presence
of 30 μM peptide. We included the Jurkat T-cell line
as a control. As we observed in Jurkat cells (Figures 10
and 11a), the NYAD-36, -66, and −67 peptides strongly
inhibited replication of WT NL4-3 in PBMC (Figure 11b-d).
However, in contrast to the results obtained in Jurkat
cells, we found that replication of the V120Q/A327P
mutant was severely attenuated in the PBMC from all
three donors. This result is not entirely surprising, given
the high degree of conservation of gp120 residues V120
and A327 (see Discussion). Although the low level of
V120Q/A327P virus replication made the antiviral activity
of the peptides difficult to assess in PBMC, it appeared
that NYAD-36, -66, and −67 showed some antiviral ac-
tivity against the V120Q/A327P mutant in this cell type.
The i,i + 7 stapled peptides retain some inhibitory activity
against V120Q/A327P-mutant virions produced in the
presence of peptide
The data presented thus far suggest that the i,i + 7 sta-
pled peptides exhibit inhibitory activity directed against
both Gag and Env. The anti-CA inhibition can be elic-
ited during the assembly phase of the virus replicationcycle if peptide is present in the virus-producer cell (see
Figure 7). This CA-based effect should not be affected by
the mutations in Env that induce resistance in a spreading
infection in Jurkat cells. To test this hypothesis, we ana-
lyzed the infectivity of Env mutant virions produced in the
presence of stapled peptides. We transfected 293T cells
with WT and V120Q/A327P molecular clones, and six
hours later treated with varying concentrations of sta-
pled peptides. Virus-containing supernatants were har-
vested, normalized for RT activity, and used to infect
TZM-bl cells. As shown in Figure 12, both WT and
V120Q/A327P virions produced from NYAD-36, -66,
and −67-treated cells showed similar reductions in par-
ticle infectivity. These results suggest that although re-
sistance mutations map to Env, and confer resistance to
the peptides both in single-cycle infectivity assays when
peptide is present only at the time of infection and in
replication assays, these stapled peptides are still able to
exert an inhibitory activity when the V120Q/A327P mu-
tant is produced in 293T cells in the presence of pep-
tides. These results support the hypothesis that i,i + 7
stapled peptides exert a dual effect by inhibiting both
Env and CA. Mutations in Env overcome the defects
imposed during entry, but do not provide resistance to
the CA-related defects.
VSV-G-pseudotyped HIV-1 particles prepared in the presence
of i,i + 7 stapled peptides are defective in single-cycle
infectivity
To investigate the potential dual-targeting of the peptides,
we examined whether they are able to inhibit the infect-
ivity of VSV-G-pseudotyped particles, which should be
resistant to an Env-dependent entry defect but not to a
CA-based effect. We also included as controls particles
Figure 11 The Env mutant V120Q/A327P is replication defective in PBMC. Jurkat T-cell line (a) and PBMCs (b-d) were infected with RT-normalized
WT- and V120Q/A327P mutant viruses and cultured in the presence of 30 uM stapled peptides and replication was monitored as described in the Figure 8
legend. The replication of HIV-1 is shown in PBMCs from three different donors (b-d).
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cells were cotransfected with an Env-defective pNL4-3
derivative (pNL4-3/KFS) and vectors expressing WT or
V120Q/A327P Env, or VSV-G. Six hours after transfec-
tion, cells were treated with 50 μM stapled peptide andFigure 12 V120Q/A327P mutant virions produced in the presence of
293T cells were transfected with WT and V120Q/A327P molecular clones, s
concentrations of NYAD-36, -66, and −67 and virions were collected after 2
TZM-bl cells and infectivity was measured as described in legend to Figurevirions were collected after two days and used to infect
TZBM-bl cells. The results indicated that the infectivity
of all of the pseudotyped particles was reduced by the
peptides. Particles bearing WT HIV-1 Env were more
significantly inhibited than those bearing either the V120Q/stapled peptides were defective in single-cycle infectivity assay.
ix hours posttransfection cells were treated with indicated
days as in Figure 7. RT-normalized virus stocks were used to infect
7. N = 6, ± SD.
Figure 13 VSV-G pseudotyped HIV-1 particles prepared in the presence of stapled peptides are also defective in single-cycle infectivity.
293T cells were cotransfected with an Env-defective pNL4-3 derivative (pNL4-3/KFS) and vectors expressing WT or V120Q/A327P Env, or VSV-G
expression vector. Six hours after transfection cells were treated with 50 μM of stapled peptides, and virions were collected after 2 days. TZM-bl
cells were infected with RT-normalized virus and infectivity was measured as described in legends to Figure 7. N = 6, ± SD.
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are consistent with inhibitory activity that is both Env-
dependent and Env-independent.Pseudotyping with VSV-G reverses the ability of the
peptides to inhibit virus infectivity when present during
infection
As shown above (Figure 10), i,i + 7 stapled peptides in-
hibit the infectivity of HIV-1 when present at the time of
infection and during virus production. The Env mutant
V120Q/A327P is largely resistant to the peptide-induced
entry block but remains susceptible to peptide-induced
defects imposed during virus production in 293T cells.Figure 14 Infectivity defects in the presence of stapled peptides are r
with VSV-G as described in Figure 13. RT-normalized WT HIV-1 Env- and VSV-G
50 μM of stapled peptides for 2 h. Two days after infection luciferase activity wThese results suggest that VSV-G pseudotyping could
potentially overcome the defect elicited by the peptides
at the time of infection. Indeed, we observed that parti-
cles bearing VSV-G were not inhibited by the presence
of peptide during the 2 hour infection period (Figure 14).
In contrast, as shown earlier, the infectivity of parti-
cles bearing HIV-1 Env was severely inhibited under
these conditions.i,i + 7 stapled peptides potently inhibit a large panel of
HIV-1 Env-pseudotyped reference viruses
Because of the high variability between HIV-1 Env gly-
coproteins from different HIV-1 isolates, we tested theeversed by VSV-G pseudotyping. HIV-1 virions were pseudotyped
-pseudotyped virions were used to infect TZM-bl cells in the presence of
as xmeasured as in Figure 7. N = 6, ± SD.
Zhang et al. Retrovirology 2013, 10:136 Page 12 of 20
http://www.retrovirology.com/content/10/1/136peptides against a large panel (total 36) of diverse HIV-1
subtype A, A/D, A2/D, AG, B, C and D reference Env-
pseudotyped viruses in a single-cycle assay. It has been
reported that these pseudoviruses exhibit a neutralization
phenotype that is typical of most primary HIV-1 isolates
and they include a wide spectrum of genetic, antigenicTable 2 Antiviral activity (IC50) of i & i + 7 stapled peptides ag
pseudotyped reference viruses
NIH # ENV clone Subtyp
11887 Q259env.w6 A
11891 QF495.23M.ENV.A3 A
11892 QF495.23M.ENV.B2 A
11894 QG984.21M.ENV.A3 A
11896 QH343.21M.ENV.A10 A
11897 QH343.21M.ENV.B5 A
11901 QA790.204I.ENV.A4 A/D
11903 QA790.204I.ENV.C8 A/D
11904 QA790.204I.ENV.E2 A/D
11905 QG393.60M.ENV.A1 A2/D
11906 QG393.60M.ENV.B7 A2D
11907 QG393.60M.ENV.B8 A2/D
11591 CRF02_AG Clone 211 AG
11595 CRF02-AG Clone 251 AG
11599 CRF02-AG Clone 257 AG
11604 CRF02_AG Clone 271 AG
11022 PVO, clone 4 (SVPB11) B
11023 TRO, Clone 11 (SVPB12) B
11035 pREJO4541 clone 67 (SVPB16) B
11036 pRHPA4259 clone 7 (SVPB14) B
11037 pTHRO4156 clone 18 (SVPB15) B
11038 pCAAN5342 clone A2 (SVPB19) B
11058 SC422661, clone B (SVPB8) B
11507 HIV-25925-2, clone 22 C
11508 HIV-26191-2, clone 48 C
11307 Du172.17 C
11308 Du422.1 C
11310 ZM214M.PL15 C
11313 ZM53M.PB12 C
11314 ZM109F.PB4 C
11317 CAP210.2.00.E8 C
11911 QA013.70I.ENV.H1 D
11912 QA013.70I.ENV.M12 D
11913 QA465.59M.ENV.A1 D
11914 QA465.59M.ENV.D1 D
11916 QD435.100M.ENV.B5 Dand geographic diversity [39,40]. The results (Table 2) in-
dicate that all three stapled peptides tested against the
pseudoviruses in single-cycle assay showed broad anti-
HIV-1 activity independent of the viral subtype. Most
significantly, NYAD-67 was the most active and showed
consistent potent antiviral activity with an IC50 rangingainst HIV-1 subtype A, A/D, A2/D, AG, B, C and D ENV
e NYAD-36 NYAD-66 NYAD-67
IC50 (μM) IC50 (μM) IC50 (μM)
3.5 ± 0.1 0.97 ± 0.04 0.22 ± 0.02
3.9 ± 0.3 3.1 ± 0.26 1.6 ± 0.06
4 ± 0.7 1.8 ± 0.2 0.9 ± 0.1
8.4 ± 0.5 1.9 ± 0.2 0.059 ± 0.01
3.6 ± 0.2 0.38 ± 0.03 0.56 ± 0.08
2 ± 0.25 2.2 ± 0.1 0.59 ± 0.09
1.3 ± 0.3 0.63 ± 0.06 0.22 ± 0.02
2 ± 0.3 1.2 ± 0.2 0.36 ± 0.06
1.9 ± 0.1 1 ± 0.1 0.47 ± 0.04
6.5 ± 1.2 1.1 ± 0.22 1.1 ± 0.11
~10.8 9 ± 0.9 2.1 ± 0.2
7.9 ± 0.6 10.4 ± 0.6 1.8 ± 0.06
9.4 ± 0.2 15.3 ± 0.7 1.8 ± 0.05
4.1 ± 0.3 1.1 ± 0.08 0.95 ± 0.03
3.9 ± 0.17 2.2 ± 0.26 0.62 ± 0.02
2 ± 0.05 3 ± 0.2 0.15 ± 0.01
1.6 ± 0.2 0.43 ± 0.08 0.26 ± 0.006
7.7 ± 0.8 >14 2.3 ± 0.2
5.7 ± 0.6 8.2 ± 0.2 0.84 ± 0.03
3.1 ± 0.3 0.66 ± 0.17 0.42 ± 0.1
3.6 ± 0.32 1.7 ± 0.15 0.48 ± 0.01
4.8 ± 0.6 0.77 ± 0.13 0.47 ± 0.06
7.1 ± 0.5 3.8 ± 0.2 1.8 ± 0.1
6.8 ± 0.3 1.3 ± 0.15 1 ± 0.13
4.5 ± 0.3 1.5 ± 0.4 2.6 ± 0.5
3.5 ± 0.15 1.8 ± 0.1 0.47 ± 0.02
2.3 ± 0.25 1.3 ± 0.2 1.1 ± 0.11
1.9 ± 0.1 1 ± 0.06 0.39 ± 0.02
1.7 ± 0.05 1.1 ± 0.06 1.6 ± 0.2
3.3 ± 0.2 3.2 ± 0.2 0.7 ± 0.1
3.6 ± 0.05 2.5 ± 0.1 0.9 ± 0.09
3.5 ± 0.2 1.4 ± 0.3 0.48 ± 0.06
3.4 ± 0.1 2 ± 0.2 0.45 ± 0.02
1.8 ± 0.3 1.2 ± 0.1 2 ± 0.3
0.93 ± 0.1 0.98 ± 0.02 1.2 ± 0.06
10.1 ± 1.9 2 ± 0.1 0.3 ± 0.03
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no toxicity in TZM-bl cells at the highest dose tested
(100 μg/ml).
Mapping of the binding site of the stapled peptides on gp120
The series of experiments described above indicate that
the i,i + 7 stapled peptides target viral entry in an Env-
dependent manner. We therefore wanted to identify
the possible binding site of these peptides on gp120.
First, we used an optical biosensor approach to measure
the affinity of NYAD-36, NYAD-66 and NYAD-67 to
immobilize full-length Yu2 gp120 or a V3-loop-deleted
variant Yu2 gp120ΔV3. NYAD-36, NYAD-66 and NYAD-67
tightly bind to the full-length Yu2gp120 with Kd of
1.7 μM, 2.6 μM and 1.3 μM, respectively (Additional file 1:
Figure S5a-c). The deletion of V3 on Yu2Gp120 impaired
the binding of NYAD-36 and NYAD-67 by more than
5-fold.
We also used ITC to measure the binding affinity of
the stapled peptides to full-length cyclic V3 loop peptide.
Only NYAD-36 and NYAD-67 were observed to bind to
the cyclic V3 loop peptide with Kd of 0.35 ± 0.03 μM
and 0.99 ± 0.04 μM, respectively (Additional file 1:
Figure S6a-d). The reverse titration resulted in similar
binding constants. To further map the binding domain
on V3, we measured the binding affinity of NYAD-36
and NYAD-67 with a series of overlapping V3 loop pep-
tides. The results indicate that neither N-terminal nor C-
terminal V3 loop peptides bind to NYAD-36 or NYAD-67.
However, the tip of V3 loop retains binding to NYAD-36
and to NYAD-67 with Kd of 15.06 ± 3.78 μM and 8.92 ±
1.80 μM, respectively (Additional file 1: Figure S7a-c).
These binding data also suggest that the whole conform-
ation of V3 loop is important for the interaction.
Discussion
We previously reported that an i,i + 4 stapled peptide,
NYAD-1, penetrates cells and disrupts virus assembly in
both in vitro and cell-based assays. Significantly, NYAD-1
specifically inhibited HIV-1 release without affecting
the release of another lentivirus, EIAV [24]. In addition,
direct binding analyses by ITC and NMR confirmed that
NYAD-1 binds to the CTD of CA. These findings moti-
vated us to expand the scope of our drug discovery effort
on hydrocarbon-stapled peptides as assembly and mat-
uration inhibitors to an i,i + 7 series of stapled peptides.
This approach allowed us to explore residues not
available in the i,i + 4 series for enhancing binding and
antiviral activity. Both these stapling techniques gener-
ally convert linear and non-cell-penetrating peptides
to α–helical and cell-penetrating peptides. Despite the
fact that this new series of stapled peptides showed α-
helical secondary structures, their ability to penetrate cells
was somewhat less efficient compared to i,i + 4 peptides,such as NYAD-1, which has recently been confirmed to
penetrate cells through lipid bilayers even at low concen-
trations [41]. The detailed study of cell penetration by
Sun et al. [41] indicates that NYAD-1 primarily binds
to the polar-apolar interface with its helix parallel to
the lipid bilayer, which helps stretching and thinning
the membrane as was observed with other helical anti-
microbial peptides such as magainin and melittin. In the
case of i,i + 7 stapled peptides reported here, their lesser
ability to penetrate cells may be attributed to their net
charge; these peptides are acidic, whereas NYAD-1 is
neutral at physiological pH. Similar poor cell permeability
of an i,i + 7 stapled peptide, SAH-p53-4, that binds the
E3 ubiquitin ligase hDM2, was reported by Bernal et al.
in 2007 [42]. This peptide has a net charge of −2 at
physiological pH. However, this group used structure-
guided optimization to overcome the problem of cell
permeability by modifying the acidic residues, Glu and
Asp, which were not located at the binding interface, to
Gln and Asn, respectively. These modifications had no
adverse effect on the binding affinity between SAH-p53-4
and hDM2. However, when we replaced two Glu and one
Asp residues in NYAD-36 these peptides became more
toxic (NYAD-46, -58 in Table 1). One probable explan-
ation for this failure is that we used the NMR structure
of NYAD-1 [32], in the absence of any structure of i,i + 7
stapled peptides used in this study, in the structure-
guided modifications. It is possible that NYAD-46 dif-
fers from NYAD-1 in terms of its structure and CTD
binding features.
The i,i + 7 stapled peptides, which showed moderate
cell penetration, were designed based on the original
linear peptide CAI, which binds to the CA CTD and
inhibited virus assembly in vitro. Therefore, we wanted
to confirm whether these peptides bind to the CA CTD
and inhibit in vitro particle assembly. Indeed, we observed
that they not only bind to the CA CTD but also the bind-
ing affinity (Kd) of one of the most potent i,i + 7 stapled
peptides, NYAD-67 (2.63 μM), was similar to that of
NYAD-1 (2.00 μM) in ITC experiments. However, the
binding affinity of NYAD-36 was about 5-fold lower.
HSQC NMR experiments confirmed tight binding of
these peptides to mutant CA (W184A/M185A). Interest-
ingly, impaired Gag processing was observed when 293T
cells transfected with a full-length HIV-1 molecular clone
were treated with i,i + 7 stapled peptides. Furthermore,
when HIV-1 particles were produced in the presence of
these stapled peptides they showed impaired infectivity
(Figure 7). The above studies and biophysical data dem-
onstrate that these stapled peptides interact with the
CA CTD and diminish particle infectivity.
To identify the target of these stapled peptides, resist-
ant viral variants were selected in the presence of one of
the moderately active i,i + 7 stapled peptides, NYAD-36.
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was identified in the CA region; rather, resistance muta-
tions mapped to two residues in gp120: V120Q in the
C1 region and A327P at the base of the V3 loop. An
NL4-3 derivative encoding the V120Q/A327P double
mutant showed substantial resistance to NYAD-36, -66
and −67 compared to the WT NL4-3 virus. Inspection
of gp120 sequences from 170 different HIV-1 isolates
aligned in the Los Alamos National Laboratory HIV se-
quence database (http://www.hiv.lanl.gov/content/index)
revealed >95% and >98% conservation of Val (V) at pos-
ition 120 and Ala (A) at position 327, respectively. These
findings explain the broad anti-HIV-1 activity of these
peptides, especially NYAD-67, which showed consist-
ently potent activity against a large panel of viruses from
the different clades we tested, including representatives
from clade C that is responsible for more than 50% of
infections worldwide. It is noteworthy that in all selec-
tion experiments these two mutations arose together. It
is currently not clear what role each of these mutations
plays in conferring resistance; the x-ray structure of
gp120 (pdb:1G9M) shows that V120 and A327 are >27Å
apart but they are both on the CD4-binding interface of
gp120 suggesting that they may play a significant role in
HIV-1 entry. V120 is located near the C-terminus of C1,
which is in close proximity to two of the CD4-binding
site residues (P124 and V127 in HIV-1 HXB2 and NL4-3)
near the V1 loop. A327P is located at the stem of V3 loop,
which has been shown to play a critical role in HIV-1 cor-
eceptor binding [43,44]. Suphaphiphat et al. reported that
an A327G mutation had very little effect on CCR5 binding
but it substantially reduced HIV-1 infectivity [45]. Indeed,
in their study, a major effect on infectivity was observed
for mutations of most of the residues in the C-terminal
portion of the V3 loop stem. We speculate that the A327P
mutation arose in response to direct binding of the nega-
tively charged stapled peptides, NYAD-36, -66 and −67, to
the highly positively charged RKSIRIQRGPGR (in NL4-3
virus) motif around the crown of the V3 loop. Direct
binding analysis by SPR using full-length Yu2 gp120 or
a V3-loop-deleted variant Yu2 gp120ΔV3 supports this
hypothesis (Additional file 1: Figure S5). The importance
of both the crown and stem region of V3 has been re-
ported in the binding of gp120 to CCR5 in mediating virus
entry [46]. A recent report by Yokoyama et al. showed that
the recombinant virus with a gp120 V3 loop carrying a
net charge of +3, but not with net charge of +7, was resist-
ant to neutralization by CD4 binding site targeted anti-
bodies [47]. We [48,49] and others [50,51] have reported
the effect of negatively charged compounds that bind to
the V3 loop and elicit antiviral activity. The negatively
charged compounds and peptides may alter the net charge
of the V3 loop and thereby elicit similar effect. Recently,
Yuan et al. showed by molecular dynamic (MD) simulationsof wild type (WT) and maraviroc-resistant gp120 V3
loop that the mutations in the stem region might affect
the structural dynamics of the loop, and it was sug-
gested that changes in loop dynamics and/or orientation
might confer resistance to maraviroc [52] by inhibiting
interactions with cellular coreceptors. Taken together the
results suggest that these peptides act as bi-functional
antiviral agents by targeting gp120 to inhibit virus entry
and CA to disrupt CA function. Similar bi-functional ef-
fects of betulinic acid derivatives have been reported [53].
Chemical modification of the side chains at C-3 and C-28
in betulinic acid conferred maturation inhibitor and entry
inhibitor activity, respectively. When both side chain mod-
ifications were incorporated in the new derivatives they
became bi-functional and the potency was enhanced by
at least 20 times compared to one of the most potent
maturation inhibitors and clinical candidates, bevirimat
or the entry inhibitor lead compound IC9564.
We note that while the gp120 mutations selected dur-
ing propagation of NL4-3 in the Jurkat T-cell line con-
ferred nearly complete resistance to the peptides in virus
replication assays in Jurkat cells (Figure 10), some inhibi-
tory peptide activity remained when the mutant virus
was produced in 293T cells in the presence of peptide
and infectivity assayed in the HeLa-based TZM-bl indi-
cator cell line (Figure 12). This was also the case when
the Env mutant was propagated in PBMC (Figure 11).
We hypothesize that the observation of full resistance in
Jurkat and partial resistance in the single-cycle assays
and PBMC replication assays may reflect differential up-
take or activity of the peptides in different cell types; as
one would expect, the mutations in V3 are sufficient to
largely counteract the entry defect conferred by the pep-
tides but would not affect their CA-targeted antiviral ac-
tivity. This is also consistent with the observation that
the previously described peptide NYAD-1 [24] is active
against both WT and the Env mutant virus in single-
cycle infectivity assays.
Conclusion
In conclusion, the in-depth mechanistic study of i,i + 7
peptides reported here suggests that the design of sta-
pled peptides is critical and it might have significant in-
fluence on the ability of the stapled peptides to target a
single step or multiple steps in HIV-1 life cycle. The study
presented here is expected to be useful in optimizing these
lead peptides to more active and selective inhibitors.
Methods
Cells, virus and compounds
The MT-2 T-cell line [obtained through the NIH AIDS
Research and Reference Reagent Program (ARP) from
Dr. D. Richman] and the Sup-T1 T-cell line (obtained from
Dr. James Hoxie) [54] were grown in RPMI 1640 medium
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(FBS), penicillin and streptomycin. TZM-bl cells (a HeLa
cell line derivative that expresses CD4, CXCR4 and CCR5
and expresses luciferase and ß-galactosidase under con-
trol of the HIV-1 promoter, obtained through the NIH
ARP from Dr. John C. Kappes, Dr. Xiaoyun Wu and
Tranzyme Inc) [55,56], HEK 293T cells (ATCC) were
grown in Dulbecco's modified Eagle's medium (DMEM)
(Invitrogen) supplemented with 10% FBS, penicillin and
streptomycin. PBMCs were isolated and cultured as
previously described [57]. The HIV-1 molecular clones
HIV-1IIIB and pNL4-3 were obtained through the NIH
ARP from Dr. R. Gallo and M. Martin, respectively.
Plasmid pNL4-3.Luc.R-.E- (Dr. N. Landau) [58,59] and
pSG3Δenv DNA (Drs. J.C. Kappes and X. Wu) [56,60],
were obtained through the NIH ARP. Env expression
vector pHXB2-env (X4) was obtained through the NIH
ARP from Dr. K. Page and Dr. D. Littman [61] and Env
expression vector pSVIIIenv-ADA was kindly provided
by Dr. JG Sodroski [62]. Clones representing the standard
HIV panels A, A/D, A2/D and D were obtained through
the NIH ARP from Dr. Julie Overbaugh [63,64]. The panel
of subtype A/G Env clones were also obtained through
the NIH ARP from Drs. Ellenberger, D., Li, B., Callahan,
M., and Butera, S. [65]. The HIV-1 Env panel of standard
reference subtype B Env clones were obtained through
the NIH ARP from Drs. David Montefiori, Feng Gao
and Ming Li (PVO, clone 4 (SVPB11), TRO, Clone 11
(SVPB12), SC422661, clone B (SVPB8)); from Drs. B.H.
Hahn and J.F. Salazar-Gonzalez (pREJO4541 clone 67
(SVPB16), pRHPA4259 clone 7 (SVPB14)); from Drs. B.H.
Hahn and D.L. Kothe (pTHRO4156 clone 18 (SVPB15),
pCAAN5342 clone A2 (SVPB19)) [39,56,60]. The subtype
C HIV-1 reference panel of Env clones were also obtained
through the NIH ARP from Drs. D. Montefiori, F. Gao,
S. Abdool Karim and G. Ramjee (Du172.17); from
Drs. D. Montefiori, F. Gao, C. Williamson and S. Abdool
Karim (Du422.1), from Drs. B. H. Hahn, Y. Li and J.F.
Salazar-Gonzalez (ZM214M.PL15); from Drs. E. Hunter and
C. Derdeyn (ZM53M.PB12 and ZM109F.PB4); from Drs. L.
Morris, K. Mlisana and D. Montefiori, (CAP210.2.00.E8)
[39,66,67]. The subtype C Indian Env clones (HIV-25925-2,
clone 22 and HIV-26191-2, clone 48) were obtained from
Drs. R. Paranjape, S. Kulkarni and D. Montefiori [65].
Full-length V3 peptide (Cat# 1840), cyclic V3 peptide
(Cat# 1837) and 15-mer overlapping V3 peptides (Cat#
1832, 6282, 6283, 6284, 6285, 6287, 6288, 6289, 6290 and
6291, for amino acid sequence see HIV-1 Subtype B (MN)
Env Peptides - Complete Set Cat# 6451) were obtained
through the NIH ARP.
Molecular cloning, protein expression and purification
pET14b or pET28a plasmids encode Gag-derived pro-
teins from the HIV-1 NL4-3 strain. The full-length gagexpression vector was subcloned from HIV-1 NL4-3
strain. The CA coding region was obtained by PCR amp-
lification and was inserted into the pET28a vector. The
C-CA (CTD) DNA fragment was provided by Drs. Ming
Luo and Peter E Prevelige Jr [68]. The C-CA (CTD) DNA
fragment was subcloned into the pET14b vector. The CTD
mutant (W184A/M185A) was generated from pET14b-C-
CA using Stratagene's QuikChange® Site-Directed Muta-
genesis Kit following the manufacture’s protocol. The
corresponding proteins (including 15N or 15N/13C labeled
mutant C-CA and C-CA) were expressed and purified as
described previously [68]. Protein concentrations were
determined with the A280 molar extinction coefficients
of 2,980 M-1cm-1(CTD, mutant), 8,480 M-1cm-1(CTD),
33,460 M-1cm-1(CA) and 64,400 M-1cm-1 (Gag), respectively.
Synthesis of the i,i + 7 stapled peptides
The peptides were synthesized manually by Fmoc solid phase
synthesis using Rink amide MBHA resin (0.3-0.4 mmol/g).
For the normal amino acids, the couplings were per-
formed with four-fold excess of amino acids. Fmoc-amino
acids were activated using the ratio of Fmoc-amino acid:
HBTU:HOBt:DIEA, 1:1:1:2. For (S)-N-Fmoc-2-(4′-pentenyl)
alanine (Fmoc-S5-OH, Okeanos Tech Co. Ltd) and (R)-N-
Fmoc-2-(7′-octenyl)-alanine (Fmoc-R8-OH, Okeanos Tech
Co. Ltd), the double coupling was performed with two-
fold excess of amino acid which was activated with DIC:
HOAt (1:1) or HCTU. For peptide olefin metathesis, the
peptide resin with N-terminal protected by Fmoc group
was treated with degassed 1, 2 dichloroethane contain-
ing Bis(tricyclohexylphosphine)-benzylidine ruthenium
(IV) dichloride (10 mM) at room temperature for two
hours and the reaction was repeated once for completion.
After de-Fmoc, the resin bound peptide was cleaved using
standard protocols (95% TFA, 2.5% water, 2.5% TIS). The
cleaved peptide was purified by RP-HPLC using 0.1% (v/v)
TFA/water and 0.1% (v/v) TFA/acetonitrile and its identity
was confirmed using electrospray mass spectroscopy.
Pseudovirus preparation
Pseudoviruses capable of single-cycle infection were ob-
tained by transfecting HEK 293T cells as previously de-
scribed [17]. Briefly, 5x106 HEK 293T cells were seeded in
a T75 flask and 24 h later, transfected in 15ml medium
with a mixture of 10 μg of an env-deleted proviral back-
bone plasmid, pNL4-3.Luc.R-.E- DNA or pSG3Δenv DNA
and 10 μg of an Env expression vector using FuGENE 6
(Roche) following manufacturer’s instructions. Pseudovirus-
containing supernatants were collected 2 days after trans-
fection, filtered and stored in aliquots at −80°C.
Virus assembly and release assays
293T cells, plated at 3 × 105 cells/well in 12 well plates,
were transfected with the HIV-1 molecular clone pNL4-
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indicated concentrations of NYAD-36, -66, and −67 for
16–20 h. One day posttransfection, cells were metabol-
ically labeled with [35S]Met/Cys for 2 h. The labeled virions
were pelleted in an ultracentrifuge, and the virus and cell
lysates were immunoprecipitated with pooled sera from
HIV-1-infected patients (HIV-Ig, obtained from the ARP)
and subjected to SDS-PAGE. Protein band intensities
were quantified by phosphorimager analysis, and virus
release was calculated as the amount of virion-associated
Gag as a fraction of total (cell- plus virion-associated) Gag
synthesized during the metabolic labeling period. Accu-
mulation of Pr55Gag in cells was measured by calculating
the ratio of Pr55Gag to p24 (CA).
Single-cycle infection assay
The inhibitory activity of i,i + 7 stapled peptides NYAD-36,
NYAD-66 and NYAD-67 was measured on HIV-1 pseudo-
typed viruses expressing Env from the panel of standard
reference subtype A, A/D, A2/D, AG, B, C and D. Pseudo-
viruses were obtained by transfecting HEK 293T cells
with a mixture of an Env-deleted backbone proviral
plasmid pSG3Δenv and an Env expression vector DNA.
Briefly, for the neutralization assay 100 μl of TZM-bl
cells at 1 × 105 cells/ml were added to the wells of a 96-well
tissue culture plate and cultured at 37°C overnight. 50 μl
of a staple peptide at graded concentrations was mixed
with 50 μl of the HIV-1 pseudovirus at about 100 TCID50
(50% tissue culture infectious dose). After incubation at
37°C for 30 min, the mixture was added to the cells and
incubated at 37°C for 3 days. Cells were washed 2 times
with PBS and lysed with 50 μl of cell culture lysis reagent.
20 μl of lysates were transferred to a white 96-well plate
and mixed with 100 ul of luciferase assay reagent. The
luciferase activity was immediately measured as above
to calculate IC50 (Luciferase Assay System, Promega).
The luciferase activity was immediately measured with a
Tecan Infinite M100 reader (Tecan, USA) and the IC50
values were calculated by the GraphPad Prism software
(GraphPad Software, Inc., USA).
TZM-bl cells were seeded at 1 × 104 cells/well in 96
well plates; one day later cells were infected with reverse-
transcriptase (RT)-normalized virus stocks for 2 h. Stapled
peptides (NYAD-1, -36, -66, -67) were added during the
2 h infection period at indicated concentrations. Two
days postinfection, cells were washed with PBS, lysed in
luciferase lysis buffer (Promega) and luciferase activity
was measured with luciferase assay substrate (Promega).
In experiments where virus-producing cells were treated
with the peptides, six-hour posttransfection 293T cells were
treated with indicated concentrations of NYAD-36, -66,
or −67, and virus supernatant was collected after
2 days. Env pseudotyped viruses were generated by cotrans-
fecting 293T cells with an Env-defective pNL4-3 derivative(pNL4-3/KFS) [70] and HIV-1 Env expression vector
pIIINL4env [71,72], pIIINL4env-V120Q/A327P, or VSV-G
expression vector pHCMV-G [73].
Multi-cycle infection assay
The inhibitory activity of i,i + 7 stapled peptides on in-
fection by laboratory-adapted HIV-1IIIB strain was deter-
mined as previously described [24]. In brief, 104 MT-2 cells
were infected with HIV-1IIIB at 100 TCID50 (0.01MOI) in
the presence or absence of test compounds at graded con-
centrations and incubated overnight. The culture superna-
tants were then replaced with fresh media. On the fourth
day post-infection, 100 μl of culture supernatants were
collected from each well, mixed with equal volume of
5% Triton X-100 and tested for p24 antigen by sandwich
ELISA. The percentage of inhibition of p24 production
and IC50 values were calculated with the GraphPad
Prism software (GraphPad Software Inc.).
Determination of cytotoxicity
In MT-2 cells
Cytotoxicity of stapled peptides in MT-2 cells was mea-
sured with the XTT (Sodium 3’-[1-phenylamino-carbonyl]-
3,4-tetrazolium]-bis[4-methoxy-6-nitro]benzenesulfonic
acid hydrate) method as previously described [24]. Briefly,
100 μl of a stapled peptide at graded concentrations was
added to an equal volume of cells (105cells/ml) in 96-well
plates followed by incubation at 37°C for 4 days. Following
addition of XTT (PolySciences, Inc.), the soluble intracellu-
lar formazan was quantitated colorimetrically at 450 nm 4 h
later. The percent of cytotoxicity and the CC50 values were
calculated with the GraphPad Prism software (GraphPad
Software Inc.).
In TZM-bl cells
The cytotoxicity of stapled peptides in TZM-bl cells was
also measured by the colorimetric method using XTT.
Briefly, 100 μl of a compound at graded concentrations
was added to equal volume of cells (105/ml) in wells of
96-well plates followed by incubation at 37°C for 3 days.
Following addition of XTT the soluble intracellular for-
mazan was quantitated as described above.
Selection and characterization of NYAD-resistant viruses
and virus replication assays in the Jurkat T-cell line and
PBMCs
NYAD-36-resistant viral isolates were selected by pro-
longed serial passage of wild-type (WT) NL4-3 in Jurkat
cells in the presence of 25, 37.5 and 50 μM NYAD-36.
Virus replication during the selection process was moni-
tored by RT activity as previously described [74]. Virus
supernatants and cell pellets were collected on the days
of peak RT activity. RT-normalized viruses were used to
infect fresh Jurkat cells, and virus replication was examined
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identify the mutations conferring resistance to NYAD-36,
genomic DNA was extracted from cells on the day of peak
RT activity using a whole blood DNA purification kit
(Qiagen). The entire Gag and Env coding region was amp-
lified by PCR and sequenced. Putative resistance-conferring
mutations were introduced into the Env expression vector
pIIINL4env by site-directed mutagenesis (Stratagene) using
mutagenic oligonucleotides. Following sequence confirm-
ation, the EcoRI-NheI fragment was cloned back into the
WT pNL4-3 to generate a molecular clone containing
the Env mutations, which were confirmed by sequen-
cing. PBMCs isolated from healthy donors were activated
by phytohemagglutinin (PHA) and were infected with RT-
normalized WT- and V120Q/A327P mutant viruses and
replication was carried out in the presence of 30 M
NYAD-36, -66, or −67. Virus supernatant was collected
every 2 or 3 days, and RT activity was monitored as above.
NMR studies
A pET11a plasmid containing DNA for a monomeric
HIV-1 CA, p24-W184A/M185A, with a C-terminal His
tag was transformed into Rosetta 2 (DE3) cells (EMD)
for protein expression. The His-tag was not removed prior
to NMR and turbidity studies. 15N isotopically labeled
protein was expressed in a minimal media solution sup-
plemented with 15NH4Cl. Protein overexpression was
induced with 1mM IPTG at an OD600 of 0.6 overnight
at 37°C. After expression, the cells were harvested by
centrifugation and lysed using a microfluidizer (Micro-
fluedics) using lysis buffer containing 50 mM NaPO4
[pH 7.4] 5 mM BME and 10 mM imidazole. Lysed cells
were then centrifuged and the soluble fraction was ap-
plied to a cobalt resin (Thermo Scientific) for purifica-
tion. The resin was washed with lysis buffer and CA was
eluted with lysis buffer containing 250 mM imidazole.
Pure protein was dialyzed in NMR buffer containing
50 mM NaOAc [pH 5.5] 5 mM DTT with 10%D2O.
The NMR-based titrations were collected at 35°C on a
Bruker AVANCE III 600 MHz equipped with a cryogenic
probe. Staple peptides were dissolved in 100% DMSO
and titrated into the monomeric HIV-1 CA, p24-W184A/
M185A, in a buffer containing 50 mM NaOAc [pH 5.5]
5 mM DTT with 10%D2O. Increasing molar ratios of
staple peptides were added into the protein and chem-
ical shift perturbations were monitored.
Circular dichroism spectroscopy
Circular dichroism (CD) spectra were obtained on an
Aviv model 62DS CD spectrometer (Aviv, Lakewood, NJ)
at 25°C using the standard measurement parameters in
1× PBS in the presence of 1–20% (v/v) acetonitrile at a
final concentration of 100 μM. In all samples, the final
concentrations of peptides and salt were always thesame, and the spectra were corrected by subtracting the
CD spectrum of the appropriate reference solvent.
Confocal microscopy
For the cell penetration study, 293T cells were seeded in
4-well chamber plates and incubated at 37°C with 5 μΜ
of FAM-conjugated peptides for 20 h in medium contain-
ing serum. After three washes with 1X PBS, live cells were
examined and imaged under a Zeiss LSM510 laser scan-
ning confocal microscope (Zeiss).
FACS Analysis of FAM-conjugated Peptide Treated Cells
297-T cells were grown in RPMI 1640 (Gibco), 10% fetal
bovine serum, 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 2 mM glutamine, 50 mM Hepes pH 7, and 50 μM
ß-mercaptoethanol. 293-T cells (6x105/well) in 2 ml
serum-free media were treated with FAM-conjugated
NYAD-1, NYAD-66, NYAD-67, NYAD-36 and NYAD-41.
The final concentration of the corresponding FAM-
conjugated peptides is 2 μM, 4 μM or 8 μM. After 4 hours
(data not shown) or 20 hours incubation with the FAM-
conjugated peptides at 37°C, the treated cells were washed
twice with 1x PBS. After a treatment with 0.25% Trypsin-
EDTA (GIBCO) for 30 min at 37°C and two washes with
1× PBS, the cells were subjected to FACS analysis. The
data were analyzed by using Flowjo Software.
Electron microscopy to study inhibition of in vitro
assembly by peptides
In vitro assembly experiments were set up as described
[9,75-77] with minor modification. We used 50 mM
Na2HPO4, pH 8.0 as the dialysis buffer. The buffer used
for assembly studies also contained 0.1 ~ 2 M of NaCl.
500-Da-MWCO dialysis tubes (Spectra/Por) were used
for the peptide dialysis. Briefly, stock proteins were ad-
justed to the appropriate concentration (25 μΜ for Gag
protein or 50 μΜ for CA protein) with the Na2HPO4
buffer at pH 8.0. After incubation with varied doses of
NYAD-36, NYAD-66 and NYAD-67 for 30 min at 4°C,
the samples were dialyzed overnight in Na2HPO4 buffer
at pH 8.0 containing 100 mM NaCl at 4°C. Negative
staining was used to check the assembly. Carbon-coated
copper grids (200 mesh size; EM Sciences) were treated
with 20 μl of poly-L-lysine (1 mg/ml; Sigma) for 2 min.
20 μl of reaction solution was placed onto the grid for
2 min. Spotted grids were then stained with 30 μl of uranyl
acetate solution for 2 min. Excess stain was removed, and
grids were air-dried. Specimens were examined with a
TECNAI G2 electron microscope (FEI, OR, USA).
In vitro CA assembly
Wild-type HIV-1 CA was overexpressed and purified as
previously described [10]. Pure protein was dialyzed in
NMR buffer containing 50 mM NaPO4 [pH 8.0]. Turbidity
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spectrophotometer at a wavelength of 350 nm to moni-
tor HIV-1 in vitro assembly conducted at ambient tem-
peratures [10]. Protein samples were prepared in an
assembly buffer [50 mM NaPO4 pH 8.0]. In vitro assem-
bly reactions were prepared with 250 μl of assembly buf-
fer containing 60 μM protein. To catalyze CA assembly
250 μl of an assembly buffer containing 5M NaCl was
added. The solution was mixed by agitation and trans-
ferred a cuvette for a total delay of 20 seconds. Assem-
bly was monitored every 10 sec for the first min and
every min thereafter for a total 10 min. Assembly reac-
tions with stapled peptides were incubated in the assembly
buffer for 10 min and then centrifuged for 1 min to separ-
ate any insoluble fractions before catalyzing assembly.Isothermal titration calorimetry (ITC)
The binding affinity between CTD (W184A/M185A) and
NYAD-36, NYAD-66 or NYAD-67 was measured by ITC
at 30°C using a Microcal titration calorimeter (MicroCal
VP-ITC). Both CTD (W184A/M185A) protein and sta-
pled peptides were exhaustively dialyzed against 25 mM
sodium phosphate buffer (pH 7.3) prior to experimental
measurements. In a typical experiment, the ITC injection
syringe was loaded with 625 μM CTD (W184A/M185A)
protein, dissolved in the dialysis buffer. The calorimetric
cell (ca. 1.4 ml active volume) initially contained only
25 μM stapled peptide in the identical dialysis buffer.
Typically titrations consisted of 27 injections of 10 μl
into the calorimetric cell, with 240-s equilibration be-
tween injections. Both forward and reverse titrations
were used to confirm the interactions between V3 loop
peptide and stapled peptides.
For forward titration, 90 μM full-length V3 peptide,
full-length cyclic V3 peptide or 90 μM 15-mer V3 peptides
were titrated into 4.5 μM of stapled or linear peptides.
Reference measurements were performed by titrating
90 μM full-length V3 peptide, full-length cyclic V3 pep-
tide or 15-mer V3 peptide into buffer without peptide.
For reverse titration, 90 μM stapled peptide was titrated
into 4.5 μM full-length V3 peptide, full-length cyclic V3
peptide or 90 μM 15-mer V3 peptide. Reference mea-
surements were performed by titrating 90 μM stapled
peptide into buffer without peptide.Surface plasmon resonance (SPR)
The binding kinetics and affinity of stapled peptides to
HIV-1 Yu2gp120 (kindly provided by Dr. Peter Kwong,
Vaccine Research Center, NIH) were analyzed by SPR
(BIAcore 3000, Piscataway, NJ). The Yu2gp120 or Yu2gp120
protein with V3 loop deletion (Yu2gp120ΔV3) was cova-
lently immobilized to a CM5 sensor chip via amine groups
using the amine coupling kit (BIAcore) in 10 mM sodiumacetate buffer at pH 5.0. The immobilization level of
gp120 reached about 1,500 response units (RU).
For the binding affinity assay, the stapled peptides were
prepared as a 10 mM stock solution in 100% DMSO. Im-
mediately prior to analysis, the compounds were diluted
with Dulbecco's PBS to a final DMSO concentration of
3%. Experiments were run at 30 μl/min in running buffer
(Dulbecco's PBS containing 3% DMSO). The stapled pep-
tides at different concentrations were injected over the
target protein (gp120) and reference surfaces for 2 min,
followed by a 5 min dissociation period. The surface was
regenerated with 6.25 mM NaOH and 50 μl/min for 30 s.
The binding kinetic parameters were evaluated with
BIA-Evaluation software (BIAcore 3000, Piscataway, NJ)
in which all data sets were fit to a simple 1:1 (Langmuir)
binding model including a term for mass transport. The
data selection of the binding and dissociation curves for
fitting was based on the instruction manual of the
BIAcore 3000 instrument, in which 3–5 s of data at
association and dissociation start were eliminated.Additional file
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